Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxetumomab pasudotox in R/R B-cell NHL and CLL
NCT01030536Phase 2Completed
- Sponsor
- MedImmune
- Start
- Feb 2010
- Primary completion
- Mar 2013
- Modality
- Antibody Fragments, Immunotoxins, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of moxetumomab pasudotox in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (5 arms), sponsored by MedImmune. Primary endpoints: Maximum Tolerated Dose, Dose Limiting Toxicities and 1 more. Started Feb 2010; status: completed.
02
Drugs
moxetumomab pasudotox
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01030536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01030536.